The DOI matches its Crossref record; 136 of the 136 references it cites were found in a registry or an index.
Modeling Parkinson’s Disease With the Alpha-Synuclein Protein
Open accessAbstract
gene, which encodes α-Syn, cause familial forms of PD and are the basis of sporadic PD risk. Given the role of the α-Syn protein in the pathology of PD, animal models that reflect the dopaminergic neuronal loss and the widespread and progressive formation of α-Syn aggregates in different areas of the brain constitute a valuable tool. Indeed, animal models of PD are important for understanding the molecular mechanisms of the disease and might contribute to the development and validation of new therapies. In the absence of animal models that faithfully reproduce human PD, in recent years, numerous animal models of PD based on α-Syn have been generated. In this review, we summarize the main features of the α-Syn pre-formed fibrils (PFFs) model and recombinant adeno-associated virus vector (rAAV) mediated α-Syn overexpression models, providing a detailed comparative analysis of both models. Here, we discuss how each model has contributed to our understanding of PD pathology and the advantages and weakness of each of them. SIGNIFICANCE: Here, we show that injection of α-Syn PFFs and overexpression of α-Syn mediated by rAAV lead to a different pattern of PD pathology in rodents. First, α-Syn PFFs models trigger the Lewy body-like inclusions formation in brain regions directly interconnected with the injection site, suggesting that there is an inter-neuronal transmission of the α-Syn pathology. In contrast, rAAV-mediated α-Syn overexpression in the brain limits the α-Syn aggregates within the transduced neurons. Second, phosphorylated α-Syn inclusions obtained with rAAV are predominantly nuclear with a punctate appearance that becomes diffuse along the neuronal fibers, whereas α-Syn PFFs models lead to the formation of cytoplasmic aggregates of phosphorylated α-Syn reminiscent of Lewy bodies and Lewy neurites.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Kalia, L. V., & Lang, A. E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61393-3 · Cited by 6,184
Dauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469
The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia
Zarranz, J. J., Alegre, J., Gómez‐Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atarés, B., et al. (2004) · Annals of Neurology · doi:10.1002/ana.10795 · Cited by 2,737
Stages in the development of Parkinson’s disease-related pathology
Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H., & Del Tredici, K. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0956-9 · Cited by 2,689
Luk, K. C., Kehm, V., Carroll, J., Zhang, B., O’Brien, P., Trojanowski, J. Q., & Lee, V. M.-Y. (2012) · Science · doi:10.1126/science.1227157 · Cited by 2,563
Non-motor features of Parkinson disease
Schapira, A. H. V., Chaudhuri, K. R., & Jenner, P. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.62 · Cited by 2,053
International Parkinson's Disease Genomics Consortium (IPDGC), Nalls, M. A., Parkinson's Study Group (PSG) Parkinson's Research: The Organized GENetics Initiative (PROGENI), 23andMe, GenePD, NeuroGenetics Research Consortium (NGRC), Hussman Institute of Human Genomics (HIHG), Investigator, T. A. J. D., (CHARGE), C. F. H. A. A. R. I. G. E., North American Brain Expression Consortium (NABEC), et al. (2014) · Nature Genetics · doi:10.1038/ng.3043 · Cited by 1,895
α-Synuclein Promotes SNARE-Complex Assembly in Vivo and in Vitro
Burré, J., Sharma, M., Tsetsenis, T., Buchman, V., Etherton, M. R., & Südhof, T. C. (2010) · Science · doi:10.1126/science.1195227 · Cited by 1,812
Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease
Kordower, J. H., Chu, Y., Hauser, R. A., Freeman, T. B., & Olanow, C. W. (2008) · Nature Medicine · doi:10.1038/nm1747 · Cited by 1,722
The many faces of α-synuclein: from structure and toxicity to therapeutic target
Lashuel, H. A., Overk, C. R., Oueslati, A., & Masliah, E. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3406 · Cited by 1,622
Volpicelli-Daley, L. A., Luk, K. C., Patel, T. P., Tanik, S. A., Riddle, D. M., Stieber, A., Meaney, D. F., Trojanowski, J. Q., & Lee, V. M.-Y. (2011) · Neuron · doi:10.1016/j.neuron.2011.08.033 · Cited by 1,569
Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein
Desplats, P., Lee, H.-J., Bae, E.-J., Patrick, C., Rockenstein, E., Crews, L., Spencer, B., Masliah, E., & Lee, S.-J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903691106 · Cited by 1,485
Kim, S., Kwon, S.-H., Kam, T.-I., Panicker, N., Karuppagounder, S. S., Lee, S., Lee, J. H., Kim, W. R., Kook, M., Foss, C. A., et al. (2019) · Neuron · doi:10.1016/j.neuron.2019.05.035 · Cited by 1,397
Genetics of Parkinson's Disease
Klein, C., & Westenberger, A. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a008888 · Cited by 1,358
Mazzulli, J. R., Xu, Y.-H., Sun, Y., Knight, A. L., McLean, P. J., Caldwell, G. A., Sidransky, E., Grabowski, G. A., & Krainc, D. (2011) · Cell · doi:10.1016/j.cell.2011.06.001 · Cited by 1,341
α-Synuclein strains cause distinct synucleinopathies after local and systemic administration
Peelaerts, W., Bousset, L., Van der Perren, A., Moskalyuk, A., Pulizzi, R., Giugliano, M., Van den Haute, C., Melki, R., & Baekelandt, V. (2015) · Nature · doi:10.1038/nature14547 · Cited by 1,130
Luk, K. C., Kehm, V. M., Zhang, B., O’Brien, P., Trojanowski, J. Q., & Lee, V. M. Y. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20112457 · Cited by 1,100
Lewy pathology in Parkinson’s disease consists of crowded organelles and lipid membranes
Shahmoradian, S. H., Lewis, A. J., Genoud, C., Hench, J., Moors, T. E., Navarro, P. P., Castaño-Díez, D., Schweighauser, G., Graff-Meyer, A., Goldie, K. N., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0423-2 · Cited by 996
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
Luk, K. C., Song, C., O'Brien, P., Stieber, A., Branch, J. R., Brunden, K. R., Trojanowski, J. Q., & Lee, V. M.-Y. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908005106 · Cited by 938
Prion-like spreading of pathological α-synuclein in brain
Masuda-Suzukake, M., Nonaka, T., Hosokawa, M., Oikawa, T., Arai, T., Akiyama, H., Mann, D. M. A., & Hasegawa, M. (2013) · Brain · doi:10.1093/brain/awt037 · Cited by 867
TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity
Decressac, M., Mattsson, B., Weikop, P., Lundblad, M., Jakobsson, J., & Björklund, A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1305623110 · Cited by 753
Kirik, D., Rosenblad, C., Burger, C., Lundberg, C., Johansen, T. E., Muzyczka, N., Mandel, R. J., & Björklund, A. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-07-02780.2002 · Cited by 649
Recasens, A., Dehay, B., Bové, J., Carballo‐Carbajal, I., Dovero, S., Pérez‐Villalba, A., Fernagut, P., Blesa, J., Parent, A., Perier, C., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24066 · Cited by 632
El-Agnaf, O. M. A., Salem, S. A., Paleologou, K. E., Cooper, L. J., Fullwood, N. J., Gibson, M. J., Curran, M. D., Court, J. A., Mann, D. M. A., Ikeda, S.-I., et al. (2003) · The FASEB Journal · doi:10.1096/fj.03-0098fje · Cited by 590
The Synucleinopathies: Twenty Years On
Goedert, M., Jakes, R., & Spillantini, M. G. (2017) · Journal of Parkinson’s Disease · doi:10.3233/jpd-179005 · Cited by 569
Li, J., Uversky, V. N., & Fink, A. L. (2001) · Biochemistry · doi:10.1021/bi010616g · Cited by 513
α-Synuclein misfolding and aggregation: Implications in Parkinson’s disease pathogenesis
Mehra, S., Sahay, S., & Maji, S. K. (2019) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2019.03.001 · Cited by 499
The Lewy Body in Parkinson’s Disease and Related Neurodegenerative Disorders
Wakabayashi, K., Tanji, K., Odagiri, S., Miki, Y., Mori, F., & Takahashi, H. (2013) · Molecular Neurobiology · doi:10.1007/s12035-012-8280-y · Cited by 479
An update on the diagnosis and treatment of Parkinson disease
Rizek, P., Kumar, N., & Jog, M. S. (2016) · Canadian Medical Association Journal · doi:10.1503/cmaj.151179 · Cited by 447
Living on the edge with too many mouths to feed: Why dopamine neurons die
Bolam, J. P., & Pissadaki, E. K. (2012) · Movement Disorders · doi:10.1002/mds.25135 · Cited by 436
Gut-seeded α-synuclein fibrils promote gut dysfunction and brain pathology specifically in aged mice
Challis, C., Hori, A., Sampson, T. R., Yoo, B. B., Challis, R. C., Hamilton, A. M., Mazmanian, S. K., Volpicelli-Daley, L. A., & Gradinaru, V. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0589-7 · Cited by 405
Chu, Y., & Kordower, J. H. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.08.021 · Cited by 396
Paumier, K. L., Luk, K. C., Manfredsson, F. P., Kanaan, N. M., Lipton, J. W., Collier, T. J., Steece-Collier, K., Kemp, C. J., Celano, S., Schulz, E., et al. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.06.003 · Cited by 392
Rey, N. L., Steiner, J. A., Maroof, N., Luk, K. C., Madaj, Z., Trojanowski, J. Q., Lee, V. M.-Y., & Brundin, P. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20160368 · Cited by 388
Oueslati, A. (2016) · Journal of Parkinson’s Disease · doi:10.3233/jpd-160779 · Cited by 375
The E46K Mutation in α-Synuclein Increases Amyloid Fibril Formation
Greenbaum, E. A., Graves, C. L., Mishizen-Eberz, A. J., Lupoli, M. A., Lynch, D. R., Englander, S. W., Axelsen, P. H., & Giasson, B. I. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411638200 · Cited by 370
Deficits in dopaminergic transmission precede neuron loss and dysfunction in a new Parkinson model
Janezic, S., Threlfell, S., Dodson, P. D., Dowie, M. J., Taylor, T. N., Potgieter, D., Parkkinen, L., Senior, S. L., Anwar, S., Ryan, B., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1309143110 · Cited by 344
Alpha-synuclein oligomers: a new hope
Bengoa-Vergniory, N., Roberts, R. F., Wade-Martins, R., & Alegre-Abarrategui, J. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1755-1 · Cited by 338
Uemura, N., Yagi, H., Uemura, M. T., Hatanaka, Y., Yamakado, H., & Takahashi, R. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0257-5 · Cited by 328
Tofaris, G. K., Garcia Reitböck, P., Humby, T., Lambourne, S. L., O’Connell, M., Ghetti, B., Gossage, H., Emson, P. C., Wilkinson, L. S., Goedert, M., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.4965-05.2006 · Cited by 326
α‐synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities
Alam, P., Bousset, L., Melki, R., & Otzen, D. E. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14808 · Cited by 307
Comparative Analysis of Adeno-Associated Viral Vector Serotypes 1, 2, 5, 7, And 8 in Mouse Brain
Taymans, J.-M., Vandenberghe, L. H., Haute, C. V. D., Thiry, I., Deroose, C. M., Mortelmans, L., Wilson, J. M., Debyser, Z., & Baekelandt, V. (2007) · Human Gene Therapy · doi:10.1089/hum.2006.178 · Cited by 305
Glucocerebrosidase and its relevance to Parkinson disease
Do, J., McKinney, C., Sharma, P., & Sidransky, E. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0336-2 · Cited by 300
Alpha-synuclein and Protein Degradation Systems: a Reciprocal Relationship
Xilouri, M., Brekk, O. R., & Stefanis, L. (2013) · Molecular Neurobiology · doi:10.1007/s12035-012-8341-2 · Cited by 299
A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration
Walsh, D. M., & Selkoe, D. J. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2016.13 · Cited by 294
Polinski, N. K., Volpicelli-Daley, L. A., Sortwell, C. E., Luk, K. C., Cremades, N., Gottler, L. M., Froula, J., Duffy, M. F., Lee, V. M. Y., Martinez, T. N., et al. (2018) · Journal of Parkinson’s Disease · doi:10.3233/jpd-171248 · Cited by 288
Decressac, M., Mattsson, B., Lundblad, M., Weikop, P., & Björklund, A. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.12.013 · Cited by 286
α-Synuclein and dopamine at the crossroads of Parkinson's disease
Venda, L. L., Cragg, S. J., Buchman, V. L., & Wade-Martins, R. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2010.09.004 · Cited by 285
Diógenes, M. J., Dias, R. B., Rombo, D. M., Vicente Miranda, H., Maiolino, F., Guerreiro, P., Näsström, T., Franquelim, H. G., Oliveira, L. M. A., Castanho, M. A. R. B., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.0234-12.2012 · Cited by 271
-Synuclein Phosphorylation Enhances Eosinophilic Cytoplasmic Inclusion Formation in SH-SY5Y Cells
Smith, W. W. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.0482-05.2005 · Cited by 268
Genetic perspective on the role of the autophagy-lysosome pathway in Parkinson disease
Gan-Or, Z., Dion, P. A., & Rouleau, G. A. (2015) · Autophagy · doi:10.1080/15548627.2015.1067364 · Cited by 260
Caudo‐rostral brain spreading of α‐synuclein through vagal connections
Ulusoy, A., Rusconi, R., Pérez‐Revuelta, B. I., Musgrove, R. E., Helwig, M., Winzen‐Reichert, B., & Monte, D. A. D. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302475 · Cited by 250
Pathological alpha-synuclein propagates through neural networks
Masuda-Suzukake, M., Nonaka, T., Hosokawa, M., Kubo, M., Shimozawa, A., Akiyama, H., & Hasegawa, M. (2014) · Acta Neuropathologica Communications · doi:10.1186/preaccept-1296467154135944 · Cited by 249
Thakur, P., Breger, L. S., Lundblad, M., Wan, O. W., Mattsson, B., Luk, K. C., Lee, V. M. Y., Trojanowski, J. Q., & Björklund, A. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710442114 · Cited by 233
Xu, L., & Pu, J. (2016) · Parkinson's Disease · doi:10.1155/2016/1720621 · Cited by 230
Glucocerebrosidase and Parkinson disease: Recent advances
Schapira, A. H. V. (2015) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2015.03.013 · Cited by 219
Prots, I., Grosch, J., Brazdis, R.-M., Simmnacher, K., Veber, V., Havlicek, S., Hannappel, C., Krach, F., Krumbiegel, M., Schütz, O., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1713129115 · Cited by 216
Rey, N. L., George, S., Steiner, J. A., Madaj, Z., Luk, K. C., Trojanowski, J. Q., Lee, V. M.-Y., & Brundin, P. (2018) · Acta Neuropathologica · doi:10.1007/s00401-017-1792-9 · Cited by 215
Seeking a Mechanism for the Toxicity of Oligomeric α-Synuclein
Roberts, H., & Brown, D. (2015) · Biomolecules · doi:10.3390/biom5020282 · Cited by 212
Zhang, J., Li, X., & Li, J.-D. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00381 · Cited by 210
Oueslati, A., Schneider, B. L., Aebischer, P., & Lashuel, H. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1309991110 · Cited by 203
Klein, R. L., Dayton, R. D., Leidenheimer, N. J., Jansen, K., Golde, T. E., & Zweig, R. M. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.10.008 · Cited by 200
Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration
Duffy, M. F., Collier, T. J., Patterson, J. R., Kemp, C. J., Luk, K. C., Tansey, M. G., Paumier, K. L., Kanaan, N. M., Fischer, D. L., Polinski, N. K., et al. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1171-z · Cited by 197
Oliveras-Salvá, M., Van der Perren, A., Casadei, N., Stroobants, S., Nuber, S., D’Hooge, R., Van den Haute, C., & Baekelandt, V. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-44 · Cited by 191
Propagation of pathological α-synuclein in marmoset brain
Shimozawa, A., Ono, M., Takahara, D., Tarutani, A., Imura, S., Masuda-Suzukake, M., Higuchi, M., Yanai, K., Hisanaga, S.-I., & Hasegawa, M. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0413-0 · Cited by 190
α-Synuclein fibrils recruit peripheral immune cells in the rat brain prior to neurodegeneration
Harms, A. S., Delic, V., Thome, A. D., Bryant, N., Liu, Z., Chandra, S., Jurkuvenaite, A., & West, A. B. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0494-9 · Cited by 181
Brain-to-stomach transfer of α-synuclein via vagal preganglionic projections
Ulusoy, A., Phillips, R. J., Helwig, M., Klinkenberg, M., Powley, T. L., & Di Monte, D. A. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1661-y · Cited by 179
GDNF fails to exert neuroprotection in a rat -synuclein model of Parkinson's disease
Decressac, M., Ulusoy, A., Mattsson, B., Georgievska, B., Romero-Ramos, M., Kirik, D., & Bjorklund, A. (2011) · Brain · doi:10.1093/brain/awr149 · Cited by 178
α-synuclein aggregation and its modulation
Ghosh, D., Mehra, S., Sahay, S., Singh, P. K., & Maji, S. K. (2017) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2016.10.021 · Cited by 175
Karampetsou, M., Ardah, M. T., Semitekolou, M., Polissidis, A., Samiotaki, M., Kalomoiri, M., Majbour, N., Xanthou, G., El-Agnaf, O. M. A., & Vekrellis, K. (2017) · Scientific Reports · doi:10.1038/s41598-017-15813-8 · Cited by 175
Is Parkinson’s disease a lysosomal disorder?
Klein, A. D., & Mazzulli, J. R. (2018) · Brain · doi:10.1093/brain/awy147 · Cited by 172
Ip, C. W., Klaus, L.-C., Karikari, A. A., Visanji, N. P., Brotchie, J. M., Lang, A. E., Volkmann, J., & Koprich, J. B. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0416-x · Cited by 171
Melki, R. (2015) · Journal of Parkinson s Disease · doi:10.3233/jpd-150543 · Cited by 169
Koprich, J. B., Johnston, T. H., Reyes, M. G., Sun, X., & Brotchie, J. M. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-43 · Cited by 168
Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons
Rocha, E. M., Smith, G. A., Park, E., Cao, H., Brown, E., Hayes, M. A., Beagan, J., McLean, J. R., Izen, S. C., Perez-Torres, E., et al. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.09.009 · Cited by 160
Long-Term Health of Dopaminergic Neuron Transplants in Parkinson's Disease Patients
Hallett, P. J., Cooper, O., Sadi, D., Robertson, H. A., Mendez, I. M., & Ole Isacson, A. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.05.027 · Cited by 159
Gaugler, M. N. M., Genç, Ö., Bobela, W., Mohanna, S., Ardah, M. T., El‐Agnaf, O. M. A., Cantoni, M., Bensadoun, J., Schneggenburger, R., Knott, G. W., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0963-y · Cited by 153
Nuber, S., Rajsombath, M. M., Minakaki, G., Winkler, J., Müller, C. P., Ericsson, M., Caldarone, B. J., Dettmer, U., & Selkoe, D. J. (2018) · Neuron · doi:10.1016/j.neuron.2018.09.014 · Cited by 153
Earls, R. H., Menees, K. B., Chung, J., Gutekunst, C., Lee, H. J., Hazim, M. G., Rada, B., Wood, L. B., & Lee, J. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1909110117 · Cited by 150
Extracellular α-synuclein levels are regulated by neuronal activity
Yamada, K., & Iwatsubo, T. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0241-0 · Cited by 148
Dopamine-modified α-synuclein blocks chaperone-mediated autophagy
Martinez-Vicente, M., Talloczy, Z., Kaushik, S., Massey, A. C., Mazzulli, J., Mosharov, E. V., Hodara, R., Fredenburg, R., Wu, D.-C., Follenzi, A., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32806 · Cited by 144
Bourdenx, M., Doveró, S., Engeln, M., Bido, S., Bastide, M. F., Dutheil, N., Vollenweider, I., Baud, L., Piron, C., Grouthier, V., et al. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0222-2 · Cited by 141
Self-citationEarls, R. H., Menees, K. B., Chung, J., Barber, J., Gutekunst, C.-A., Hazim, M. G., & Lee, J.-K. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1636-8 · Cited by 138 · cited 2×
“Indeed, it has been shown that striatal injection of a-Syn PFFs but not monomers in WT mice can trigger neuroinflammation by increasing peripheral immune cells infiltration in the CNS (Earls et al., 2019).”
BackgroundResultEmmer, K. L., Waxman, E. A., Covy, J. P., & Giasson, B. I. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.247965 · Cited by 138
Machiya, Y., Hara, S., Arawaka, S., Fukushima, S., Sato, H., Sakamoto, M., Koyama, S., & Kato, T. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.141952 · Cited by 137
McFarland, N. R., Fan, Z., Xu, K., Schwarzschild, M. A., Feany, M. Β., Hyman, B. T., & McLean, P. J. (2009) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181a24b53 · Cited by 136
Modeling α-Synuclein Propagation with Preformed Fibril Injections
Chung, H. K., Ho, H.-A., Pérez-Acuña, D., & Lee, S. (2019) · Journal of Movement Disorders · doi:10.14802/jmd.19046 · Cited by 128
Seeding variability of different alpha synuclein strains in synucleinopathies
Candelise, N., Schmitz, M., Llorens, F., Villar‐Piqué, A., Cramm, M., Thom, T., Correia, S., da Cunha, J. E. G., Möbius, W., Outeiro, T. F., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25446 · Cited by 126
Koprich, J. B., Johnston, T. H., Huot, P., Reyes, M. G., Espinosa, M. C., & Brotchie, J. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017698 · Cited by 124
Volpicelli‐Daley, L. A., Kirik, D., Stoyka, L. E., Standaert, D. G., & Harms, A. S. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13627 · Cited by 124
N370S ‐GBA1 mutation causes lysosomal cholesterol accumulation in Parkinson's disease
García‐Sanz, P., Orgaz, L., Bueno-Gil, G., Espadas, I., Rodríguez‐Traver, E., Kulisevsky, J., Gutiérrez, A., Dávila, J. C., González‐Polo, R. A., Fuentes, J. M., et al. (2017) · Movement Disorders · doi:10.1002/mds.27119 · Cited by 122
Self-citationDurante, V., de Iure, A., Loffredo, V., Vaikath, N. N., Risi, M. D., Paciotti, S., Quiroga‐Varela, A., Chiasserini, D., Mellone, M., Mazzocchetti, P., et al. (2019) · Brain · doi:10.1093/brain/awz065 · Cited by 122
Intrastriatal alpha-synuclein fibrils in monkeys: spreading, imaging and neuropathological changes
Chu, Y., Muller, S., Tavares, A., Barret, O., Alagille, D., Seibyl, J. P., Tamagnan, G. D., MAREK, K. L., Luk, K. C., Trojanowski, J. Q., et al. (2019) · Brain · doi:10.1093/brain/awz296 · Cited by 119
Activation of the DNA damage response in vivo in synucleinopathy models of Parkinson’s disease
Milanese, C., Cerri, S., Ulusoy, A., Gornati, S. V., Plat, A., Gabriels, S., Blandini, F., Di Monte, D. A., Hoeijmakers, J. H., & Mastroberardino, P. G. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0848-7 · Cited by 118
Martin, Z. S., Neugebauer, V., Dineley, K. T., Kayed, R., Zhang, W., Reese, L. C., & Taglialatela, G. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07576.x · Cited by 117
New Perspectives on Roles of Alpha-Synuclein in Parkinson’s Disease
Zhang, G., Xia, Y. F., Wan, F. J., Ma, K., Guo, X., Kou, L., Yin, S., Han, C., Liu, L., Huang, J., et al. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00370 · Cited by 116
Tosatto, L., Horrocks, M. H., Dear, A. J., Knowles, T. P. J., Serra, M. D., Cremades, N., Dobson, C. M., & Klenerman, D. (2015) · Scientific Reports · doi:10.1038/srep16696 · Cited by 112
Olanow, C. W., Savolainen, M., Chu, Y., Halliday, G. M., & Kordower, J. H. (2019) · Brain · doi:10.1093/brain/awz104 · Cited by 112
Induction of de novo α-synuclein fibrillization in a neuronal model for Parkinson’s disease
Fares, M.-B., Maco, B., Oueslati, A., Rockenstein, E. M., Ninkina, N. N., Buchman, V. L., Masliah, E., & Lashuel, H. A. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1512876113 · Cited by 109
Chau, K., Ching, H. L., Schapira, A. H. V., & Cooper, J. A. D. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06191.x · Cited by 106
The remarkable conformational plasticity of alpha-synuclein: blessing or curse?
Deleersnijder, A., Gérard, M., Debyser, Z., & Baekelandt, V. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.04.002 · Cited by 105
Taschenberger, G., Garrido, M., Tereshchenko, Y., Bähr, M., Zweckstetter, M., & Kügler, S. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0926-8 · Cited by 103
Gombash, S. E., Manfredsson, F. P., Kemp, C. J., Kuhn, N. C., Fleming, S. M., Egan, A. E., Grant, L. M., Ciucci, M. R., MacKeigan, J. P., & Sortwell, C. E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081426 · Cited by 101
McFarland, N. R., Lee, J., Hyman, B. T., & McLean, P. J. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06010.x · Cited by 95
Okuzumi, A., Kurosawa, M., Hatano, T., Takanashi, M., Shuuko, N., Fukuhara, T., Yamanaka, T., Miyazaki, H., Yoshinaga, S., Furukawa, Y., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0587-0 · Cited by 92
A cell culture model for monitoring α-synuclein cell-to-cell transfer
Reyes, J. F., Olsson, T. T., Lamberts, J. T., Devine, M. J., Kunath, T., & Brundin, P. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.07.003 · Cited by 90
Castro‐Sánchez, S., García‐Yagüe, Á. J., López‐Royo, T., Casarejos, M. J., Lanciego, J. L., & Lastres‐Becker, I. (2018) · Glia · doi:10.1002/glia.23338 · Cited by 89
O’Donovan, S. M., Crowley, E. K., Brown, J. R. ‐., O’Sullivan, O., O’Leary, O. F., Timmons, S., Nolan, Y. M., Clarke, D. J., Hyland, N. P., Joyce, S. A., et al. (2020) · Neurogastroenterology & Motility · doi:10.1111/nmo.13726 · Cited by 86
Widespread and abundant α‐synuclein pathology in a neurologically unimpaired subject
Parkkinen, L., Pirttilä, T., Tervahauta, M., & Alafuzoff, I. I. (2005) · Neuropathology · doi:10.1111/j.1440-1789.2005.00644.x · Cited by 77
The L444P Gba1 mutation enhances alpha-synuclein induced loss of nigral dopaminergic neurons in mice
Migdalska‐Richards, A., Węgrzynowicz, M., Rusconi, R., Deangeli, G., Monte, D. A. D., Spillantini, M. G., & Schapira, A. H. V. (2017) · Brain · doi:10.1093/brain/awx221 · Cited by 77
Generation of Alpha-Synuclein Preformed Fibrils from Monomers and Use In Vivo
Patterson, J. R., Polinski, N. K., Duffy, M. F., Kemp, C. J., Luk, K. C., Volpicelli‐Daley, L. A., Kanaan, N. M., & Sortwell, C. E. (2019) · Journal of Visualized Experiments · doi:10.3791/59758 · Cited by 77
Viral Vector-Based Models of Parkinson’s Disease
der Perren, A. V., den Haute, C. V., & Baekelandt, V. (2014) · Current topics in behavioral neurosciences · doi:10.1007/7854_2014_310 · Cited by 74
Caudal, D., Alvarsson, A., Björklund, A., & Svenningsson, P. (2015) · Experimental Neurology · doi:10.1016/j.expneurol.2015.09.002 · Cited by 74
Cholesterol and multilamellar bodies: Lysosomal dysfunction in GBA-Parkinson disease
García‐Sanz, P., Orgaz, L., Fuentes, J. M., Vicario‐Abejón, C., & Moratalla, R. (2018) · Autophagy · doi:10.1080/15548627.2018.1427396 · Cited by 71
Self-citationAlbert, K., Voutilainen, M. H., Domanskyi, A., & Airavaara, M. (2017) · Genes · doi:10.3390/genes8020063 · Cited by 70
Alpha-synuclein-induced neurodegeneration is exacerbated in PINK1 knockout mice
Oliveras-Salvá, M., Macchi, F., Coessens, V., Deleersnijder, A., Gérard, M., der Perren, A. V., den Haute, C. V., & Baekelandt, V. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.04.032 · Cited by 66
Faustini, G., Longhena, F., Varanita, T., Bubacco, L., Pizzi, M., Missale, C., Benfenati, F., Björklund, A., Spano, P., & Bellucci, A. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1892-1 · Cited by 64
Salganik, M., Sergeyev, V., Shinde, V. M., Meyers, C., Gorbatyuk, M. S., Lin, J. H., Zolotukhin, S., & Gorbatyuk, O. S. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.02.018 · Cited by 61
Dysregulated dopamine storage increases the vulnerability to α-synuclein in nigral neurons.
Ulusoy, A., Björklund, T., Buck, K., & Kirik, D. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.05.012 · Cited by 59
Costa, C., Sgobio, C., Siliquini, S., Tozzi, A., Tantucci, M., Ghiglieri, V., Filippo, M. D., Pendolino, V., de Iure, A., Marti, M., et al. (2012) · Brain : a journal of neurology · doi:10.1093/brain/aws101 · Cited by 58
Duffy, M. F., Collier, T. J., Patterson, J. R., Kemp, C. J., Fischer, D. L., Stoll, A. C., & Sortwell, C. E. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00621 · Cited by 56
Qamar, M. A., Sauerbier, A., Politis, M., Carr, H. J., Loehrer, P. A., & Chaudhuri, К. R. (2017) · npj Parkinson s Disease · doi:10.1038/s41531-016-0006-9 · Cited by 55
Neuropathology of Nonmotor Symptoms of Parkinson's Disease
Jellinger, K. A. (2017) · International review of neurobiology · doi:10.1016/bs.irn.2017.05.005 · Cited by 55
Johansen, K. K., TORP, S. H., Farrer, M. J., Gustavsson, E. K., & Aasly, J. O. (2018) · Case Reports in Neurological Medicine · doi:10.1155/2018/6838965 · Cited by 54
Lack of functional relevance of isolated cell damage in transplants of Parkinson’s disease patients
Cooper, O., Astradsson, A., Hallett, P. J., Robertson, H. A., Mendez, I. M., & Ole Isacson, A. (2009) · Journal of Neurology · doi:10.1007/s00415-009-5242-z · Cited by 53
LAMP2A as a therapeutic target in Parkinson disease
Xilouri, M., Brekk, O. R., Kirik, D., & Stefanis, L. (2013) · Autophagy · doi:10.4161/auto.26451 · Cited by 49
Spreading of alpha‐synuclein – relevant or epiphenomenon?
Killinger, B. A., & Kordower, J. H. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14779 · Cited by 49
Lu, J., Sun, F., Ma, H., Qing, H., & Deng, Y. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.07.007 · Cited by 35
Gene therapy approaches in the non-human primate model of Parkinson’s disease
Pignataro, D., Sucunza, D., Rico, A. J., Dopeso‐Reyes, I. G., Roda, E., Rodriguez-Perez, A. I., Labandeira-García, J. L., Broccoli, V., Kato, S., Kobayashi, K., et al. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1681-3 · Cited by 26
Toxic effects of human and rodent variants of alpha‐synuclein in vivo
Landeck, N., Buck, K., & Kirik, D. (2016) · European Journal of Neuroscience · doi:10.1111/ejn.13493 · Cited by 24
G2019S LRRK2 mutation causing Parkinson’s disease without Lewy bodies
Gaig, C., Martı́, M. J., Ezquerra, M., Cardozo, A., Rey, M. J., & TOLOSA, E. S. (2009) · BMJ Case Reports · doi:10.1136/bcr.08.2008.0632 · Cited by 20
Serotonergic pathology and Braak's staging hypothesis in Parkinson's disease
Schindlbeck, K. A., & Eidelberg, D. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30242-x · Cited by 10
Cited by
Adamu, A., Li, S., Gao, F., & Xue, G. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1347987 · Cited by 564
α-Synuclein misfolding and aggregation: Implications in Parkinson’s disease pathogenesis
Mehra, S., Sahay, S., & Maji, S. K. (2019) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2019.03.001 · Cited by 499
Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent
Mehdi, S. F., Pusapati, S., Anwar, M. S., Lohana, D., Kumar, P., Nandula, S. A., Nawaz, F. K., Tracey, K., Yang, H., LeRoith, D., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1148209 · Cited by 317
Impaired dopamine release in Parkinson’s disease
Cramb, K. M. L., Beccano-Kelly, D., Cragg, S. J., & Wade-Martins, R. (2023) · Brain · doi:10.1093/brain/awad064 · Cited by 207
Progress and Challenges in Targeted Protein Degradation for Neurodegenerative Disease Therapy
Fang, Y., Wang, J., Zhao, M., Zheng, Q., Ren, C., Wang, Y., & Zhang, J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00844 · Cited by 100
Metadata
- Authors
- Gómez-Benito, M., Granado, N., García-Sanz, P., Michel, A., Dumoulin, M., & Moratalla, R.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2020-04-23
- Volume
- 11
- Pages
- 356-356
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W3016614566
- Cited by
- 437
- References
- 136
- FWCI
- 18.08
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.